Abstract
Rationale of the study: Capecitabine is potential anticancer prodrug approved for colorectal cancer and metastatic breast cancer. It has short half life and several adverse effects due to which was encapsulated in erythrocytes for the treatment of hepatocellular carcinoma to observe and compare the effect of formulation with that of plain drug. 
 Introduction: The hepatoprotective potential of Capecitabine resealed erythrocytes was evaluated using MNU induced hepatocarcinogenesis in swiss albino mice model of 4 weeks. 
 Methodology: In present study, the effects of formulation and plain drug with respect to body weight, haematological parameters, biochemical parameters and histopathological study were evaluated and compared. 
 Results: Formulation restored the normal body weight and liver architecture with slight differences. Except platelets and neutrophils, no significant differences were observed in haematological parameters. The values of antioxidant enzymes (SOD, Catalase) and AFP were also restored more with formulation than plain drug though with no statistical differences when compared with normal control. Also it reduced the lipid peroxidation in the liver in treated group Vs induced group. 
 Conclusion: All these findings demonstrated hepatoprotective and anticancer effect of Capecitabine Resealed Erythrocytes (CRE) and suggested the use of this sustained release formulation in cancer chemoprevention.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
